Rachel Teitelbaum of Hervana, Ltd. in Israel will develop and test a biological vaginal formulation that produces a sperm-binding agent, which interferes with sperm motility or fertilization or both. It is hoped that this non-hormonal contraceptive will need only infrequent administration to maintain its effectiveness. In this project's Phase I research, Teitelbaum developed a lead formulation and demonstrated initial proof-of-principle that such an approach can provide effective contraception. In Phase II, Teitelbaum and her team will expand upon this proof-of-principle in animal models to arrive at a long-acting, safe, and effective contraceptive that is ready for evaluation in human trials.
More information about Create New Technologies for Contraception (Round 4)